[Sporadic cases of hemolytic uremic syndrome and hemorrhagic colitis with serum IgM antibodies to lipopolysaccharides of enterohemorrhagic Escherichia coli O157].
In 1994-1996 summer, eight patients with hemolytic uremic syndrome(HUS) and 3 patients with hemorrhagic colitis, whose fecal specimens yielded no Enterohemorrhagic Escherichia coli(EHEC) because of the antibiotic therapies before presentation, showed serum IgM antibody responses to lipopolysaccharide(LPS) of O157. Although early bacteriological examination is essential for diagnosis, serological testing of patients with HUS or HC for antibodies to the LPS of EHEC provides evidence of infection with EHEC. We also presented successful fluoroquinolones(SPFX and NFLX) therapies of another 15 HC inpatient cases from Sakai outbreak of O157 infections due to school lunch in summer 1996. In these 15 HC patients, 12 EHECs of serotype O157:H7 with VT1 and VT2 and phage type 32 were obtained, but no growths of EHECs after fluoroquinolones therapy and no progressions to HUS resulted. The MICs of SPFX is 0.025 microgram/dl, NFLX 0.1, NA 3.13, FOM 12.5, ST 0.39, KM 3.13, ABPC 1.56-3.13.
Shiomi
M
M
Department of Pediatrics and Infectious Diseases, Osaka City General Hospital.
Togawa
M
M
D000890:Anti-Infective Agents / Q000627:therapeutic use; D003092:Colitis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology*; D004196:Disease Outbreaks; D004927:Escherichia coli Infections; D019453:Escherichia coli O157; D024841:Fluoroquinolones; D006471:Gastrointestinal Hemorrhage / Q000382:microbiology; D006463:Hemolytic-Uremic Syndrome / Q000382:microbiology; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D007564:Japan / Q000453:epidemiology; D008070:Lipopolysaccharides / Q000276:immunology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007075:Immunoglobulin M; D008070:Lipopolysaccharides